About the OncotypeDx ARV7 Test
The purpose of this test is to identify mCRPC (metastatic castration-resistant prostate cancer) patients who will NOT respond to androgen receptor (AR) targeted therapies, such as abiraterone and enzalutamide, and should therefore consider chemotherapy.
Over time, tumors can adapt (and become resistant) to AR-targeted treatments. AR-V7 Nucleus Detect is designed to detect AR-V7 proteins in the nucleus of circulating tumor cells (CTCs) in the blood. Large clinical studies found that AR-V7+ patients (patients with AR-V7 in the nucleus of CTCs) do not benefit from AR-targeted therapies, experience faster progression and lower median overall survival (compared with patients negative for AR-V7), and are substantially more likely to live longer when treated with taxane chemotherapy (1, 2). The sample is obtained through a blood draw.
Below are several resources designed to help patients and their family better understand how the OncotypeDx ARV7 test is used in a clinical setting, including a video as well as downloadable brochures.